Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biological standardization of Artemisia vulgaris allergen extract
2013-001310-15Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Sep 2013
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of artemisia vulgaris pollen allergen extract in pollinosis, sponsored by LETI Pharma. Primary endpoint: Skin prick test wheal area equivalence to histamine. Started Sep 2013; status: completed.
02
Drugs
artemisia vulgaris pollen allergen extract
03
Conditions
pollinosis
Beyond the preview
Go deeper on 2013-001310-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001310-15.